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ABSTRACT 
T Follicular helper cells (TFH) are considered critical for B cell antibody response, and recent 
efforts have focused on promoting TFH in order to enhance vaccine efficacy. We studied the 
frequency and function of TFH in nasopharynx-associated lymphoid tissues (NALT) from children 
and adults, and its role in anti-influenza antibody response following stimulation by a live-
attenuated influenza vaccine (LAIV) or an inactivated seasonal virus antigen (sH1N1). We 
further studied whether CpG-DNA promotes TFH and by which enhances anti-influenza response. 
We showed NALT from children aged 1.5-10 years contained abundant TFH, suggesting efficient 
priming of TFH during early childhood. Stimulation by LAIV induced a marked increase in TFH 
that correlated with a strong production of anti-hemagglutinin (HA) IgA/IgG/IgM antibodies in 
tonsillar cells. Stimulation by the inactivated sH1N1 antigen induced a small increase in TFH 
which was markedly enhanced by CpG-DNA, accompanied by enhanced anti-HA antibody 
responses. In B cell co-culture experiment, anti-HA responses were only seen in the presence of 
TFH, and addition of plasmacytoid dendritic cell to TFH-B cell co-culture enhanced the TFH-
mediated antibody production following CpG-DNA and sH1N1 antigen stimulation. Induction of 
TFH differentiation from naïve T cells was also shown following the stimulation. Our results 
support a critical role of TFH in human mucosal anti-influenza antibody response. Use of an 
adjuvant such as CpG-DNA that has the capacity to promote TFH by which to enhance antigen-
induced antibody responses in NALT tissue may have important implications for future 
vaccination strategies against respiratory pathogens. 
Keywords: T follicular helper cell (TFH), influenza virus, influenza vaccine, anti-hemagglutinin 
(HA) antibody response, Nasopharynx-associated lymphoid tissues (NALT), CpG-DNA, children 
and adults,  
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1. INTRODUCTION 
Follicular helper T cells (TFH) are a specialized T cell subset that provides help to B cells for 
antibody production(Crotty, 2011). The main effector site of TFH is the germinal center (GC) 
within the secondary lymphoid organs. The interaction between TFH and B cells leads to GC 
formation and the development of high affinity antibodies that are central for T cell-dependent 
antibody response, and therefore TFH are considered critical for infection- or vaccine-induced 
protective immunity(Crotty, 2014),(Slight et al., 2013). Most of the evidence supporting a critical 
role of TFH are derived from studies in mice, whereas direct evidence from humans on TFH’s role 
in vaccine-induced immunity is lacking due to the difficulty to obtain human secondary lymphoid 
tissue(Schmitt and Ueno). However, recent studies demonstrated that the response of “TFH-like” 
cells in peripheral blood following parenteral influenza vaccination correlated well with the anti-
hemagglutinin (HA) antibody response, which provide supporting evidence for the importance of 
TFH in vaccine-induced response in humans (Bentebibel et al., 2013),(Spensieri et al., 2013). 
Recently, identification of novel agent/adjuvants that promote TFH number or function thus to 
enhance antibody response has become an attractive vaccination strategy (Fazilleau et al., 2009; 
Spensieri et al., 2013).  
There is increasing interest recently in developing mucosal vaccines such as intranasally 
administered vaccines against respiratory tract infections(Lycke, 2012). Nasopharynx-associated 
lymphoid tissues (NALT) comprising of adenoids and tonsils are secondary lymphoid organs 
known to be important induction sites for natural immunity against respiratory tract pathogens 
including influenza virus(Kiyono et al., 2004). Also, they are a major induction site for immunity 
induced by intranasal vaccines, such as live-attenuated influenza vaccines (LAIV). As immune 
tolerance is a major feature of the mucosal immune system, it is generally considered that 
mucosal vaccination needs either a live-attenuated vaccine or an inactivated virus or subunit 
vaccine antigen together with an adjuvant.  LAIV has been demonstrated to be an effective 
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intranasal vaccine against influenza and been licensed for use in children over 2 years of age. 
However, LAIV is not licensed for young children < 2 years because of concerns over increased 
risk of wheezing (Belshe et al., 2007). There is a need for an alternative intranasal vaccine for this 
age group and that may include inactivated influenza virus antigens with an effective mucosal 
adjuvant.  
Dendritic cells (DC) were shown to be important to initiate TFH cell development(Goenka et al., 
2011). Within mucosal lymphoid tissue including human tonsils,  plasmacytoid DC (pDC) has 
been shown to be an important DC population (Polak et al., 2008; Rescigno, 2013). In humans, 
pDC uniquely express both TLR-7 and TLR-9 which are not found on myeloid DC (Hornung et 
al., 2002). CpG-DNA, a TLR-9 ligand, has been shown to possess adjuvant activity capable of 
enhancing antibody responses, including that intranasal administration of CpG-DNA enhanced 
antibody response to co-administered influenza vaccines in animal models (Klinman, 2006; 
McCluskie and Davis, 1999; Weeratna et al., 2000),(Moldoveanu et al., 1998). Recent studies in 
mice suggest CpG-DNA may potentiate TFH response by monocyte-derived DC to modulate 
antibody production (Chakarov and Fazilleau, 2014). However, it is not known whether CpG-
DNA promotes TFH in humans and whether pDC contribute to promoting TFH and by which 
enhances vaccine antigen-induced response.  
A central marker of TFH cells is CXC-chemokine receptor 5 (CXCR5), which is important for TFH 
positioning in GC(Schaerli et al., 2000). TFH are typically identified by co-expression of CXCR5 
together with other markers including ICOS, PD-1, BCL-6 (Breitfeld et al., 2000; Kim et al., 
2001) (Choi et al., 2011; Fazilleau et al., 2009; Kerfoot et al., 2011; King, 2009; Laurent et al., 
2010). A number of cytokines, particularly IL-21, are produced by TFH, and are considered to 
have a major role in TFH differentiation and function on B cell antibody response (King, 2009).   
In this study, we examined the role of TFH in influenza vaccines- or antigen-induced anti-HA 
response in human NALT immune cells, and studied whether a candidate adjuvant CpG-DNA 
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promotes TFH and by which potentiate the inactivated virus antigen-induced anti-influenza 
antibody responses.  
2. METHODS 
2.1. Patients and samples. Adenoidal and tonsillar tissues were obtained from patients (age 1.5–
36 years) recruited (from 2012 to 2015) for adenoidectomy and/or tonsillectomy due to upper 
airway obstruction. The tissues were transported in HBSS medium (Hank’s Balanced salt 
solution) in a cold box to the laboratory and proceeded to cell isolation within four hours. Each 
tissue sample was checked for any signs of gross inflammation and/or necrosis prior to 
processing and samples that exhibited either of these features were excluded from the study.  
Patients with known immunodeficiency and those previously vaccinated against influenza were 
also excluded from the study. The Liverpool Paediatric Research Ethics Committee approved the 
study [08/H1002/92] and written informed consent was obtained in all cases. 
2.2. LAIV vaccine, influenza virus antigens and CpG-DNA. An intranasal LAIV (FluMist, 
2009-10) that included A/Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2) and B 
influenza strains was obtained from BEI resources (Manassas,VA). 0.2ml of LAIV contains 
about 107 fluorescent focus units (FFU) of each strain. An inactivated seasonal 
A/Brisbane/59/2007 H1N1 influenza virus (sH1N1) antigen, which was inactivated by β-
propiolactone and partially purified (Wood et al., 1977) was obtained from the National Institute 
for Biological Standards and Control (NIBSC, UK). This inactivated sH1N1 antigen contained 
83ug/ml of HA. A purified recombinant HA of sH1N1 was obtained from BEI Resources and 
used as the coating antigen for anti-HA antibody measurement by ELISA and ELISpot assays.  A 
type B CpG-DNA (CpG 2006, InvivoGen) (Krieg et al., 1995)  was used to study the effect on 
TFH.  
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2.3. Cell separation, culture, and stimulation. Mononuclear cells (MNC) from adenotonsillar 
tissue were isolated using Ficoll density centrifugation (Zhang et al., 2006) (Zhang et al., 2011) 
and the number of MNC isolated from each patient ranged from 5.0x107-1.0x109. In some 
experiments, tonsillar MNC were depleted of effector and memory (CD45RO+) cells using 
CD45RO microbeads and magnetic cell sorting (Miltenyi) as described previously (Gray et al., 
2014; Zhang et al., 2007).  The depletion of CD45RO+ cells from tonsillar MNC removed TFH 
cells (>98%). Unfractionated MNC or CD45RO+cell-depleted MNC were cultured (4x106/ml) in 
96-well flat-bottom culture plates in RPMI-1640 medium with HEPES supplemented with 10% 
fetal bovine serum (FBS), 1% L-glutamine, streptomycin (50µg/ml) and penicillin (50U/ml) 
(Sigma), in the presence of CpG-DNA, inactivated sH1N1 antigen, or LAIV. Cell culture 
supernatants were collected and stored at -80°C until analysis for antibody or cytokine production 
by ELISA.  
The effect of IL21 on TFH and TFH-mediated help for antibody production was examined using 
recombinant human IL21R-Fc chimera (R&D systems) (IL21-Fc). IL21-Fc (or isotype control) 
(10µg/ml) was incubated with tonsillar MNC or with TFH-B cell co-culture for 1 hour, before the 
addition of CpG-DNA (0.1µg/ml) and/or sH1N1 antigen (1µg/ml). The cells were then cultured
 
for up to 10 days for analysis of TFH numbers and of antibody production. 
2.4. Measurement of HA-Specific antibodies. Production of HA-specific IgG, IgM and IgA 
antibodies to sH1N1 virus in cell culture supernatants was measured as previously described 
(Ahmed et al., 2015), (Mahallawi et al., 2013). In brief, ELISA plates were coated with 
recombinant HA overnight. Following blocking, cell culture supernatants were added and 
incubated for 2 hours. Alkaline phosphatase-conjugated anti-human IgG, IgM or IgA antibody 
was then added and incubated.  Following the addition of pNPP substrate, color development was 
read at OD405nm and data were analysed using DeltaSoft software. 
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2.5. Analysis of TFH,  cell proliferation and intracellular cytokine expression. For TFH 
identification, tonsillar MNC were stained with anti-human CD3, CD4, CXCR5, ICOS, CCR7, 
and Bcl-6 antibodies followed by flow cytometry (Rasheed et al., 2006). Cell proliferation was 
examined by CFSE staining of tonsillar MNC (Molecular Probes, UK), followed by cell 
stimulation for 5 days and by flow cytometry. Intracellular cytokine staining was performed 
following overnight cell stimulation as described previously (Zhang et al., 2011). Intracellular 
staining for Bcl-6 and TLR9 was performed following manufacturer’s instructions with anti-
human Bcl-6 and TLR-9 antibodies (eBioscience). Flow cytometry was performed using FACS 
Calibure (BD Biosciences) and data analyzed using WinMDI software (Scripps Institute). 
2.6. Purification of TFH, B cells and pDC. TFH, B cells and pDC were purified from tonsillar 
MNC using magnetic cell sorting (EasySep™, Stemcell). Briefly, tonsillar B cells were purified 
by negative selection using B cell purification kit which yielded B cell purity >99%. For TFH 
purification, CD4+T cells were first isolated by negative selection using CD4+ T cell kit, followed 
by positive selection of CXCR5high (TFH) using biotin anti-human CXCR5 antibody. The amount 
of anti-CXCR5 antibody was optimised to ensure only CXCR5high-expressing cells were selected 
(purity>95%). CD4+CXCR5- (non-TFH) cells were purified by negative selection from CD4+T 
cells using an optimised amount of anti-CXCR5 antibody to ensure only CXCR5- cells were 
obtained (purity >99%). Tonsillar pDC were purified using negative selection with human 
plasmacytoid DC kit (Stemcell) which yielded a pDC purity >96%. From a total of 5.0x107 
MNC, the numbers of isolated TFH, B cell and pDC were ranged 2.0-4.0x106, 1.0-1.5x107, and 
1.0-2.0x105 respectively. 
2.7. TFH-B cell co-culture. The ability of tonsillar TFH to help B cell antibody production was 
examined by an autologous B cell- TFH co-culture. Purified B cells were co-cultured (1:1 ratio) 
with either purified TFH or non-TFH cells at 5x105 cells/ml in a 96-well round bottom plate, in the 
presence of CpG-DNA and/or sH1N1 virus antigen. The cells were cultured for
 
10 days and cell 
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culture supernatant were collected for antibody analysis. In some experiments, purified pDC were 
added at a concentration of 5x104 cells/ml to the TFH-B cell co-culture.  
2.8. Statistical Analysis. Two group comparisons were analysed by student’s T test, and paired T 
test was used for comparison between paired samples. Analysis of variance (ANOVA) was used 
for multiple group comparisons. Correlation was analysed by Pearson’s correlation. Statistical 
analysis was performed using GraphPad Prism 5 software. P<0.05 was considered statistically 
significant.  
3. RESULTS 
3.1. Identification and frequency of TFH in human tonsillar tissue and its relationship with age. 
Adenotonsillar MNC were identified by staining for CD3, CD4, CXCR5 and ICOS expression 
followed by flow cytometry. Based on CXCR5 and ICOS expression in CD4+T cells, three 
populations were observed (Figure 1a): CXCR5highICOShigh CD4+T cells (red, designated as 
TFH), CXCR5intICOSint (Blue) and CXCR5-ICOS- (Green) CD4+T cells.  In addition to the high 
expression of CXCR5 and ICOS, the designated TFH population were also shown to express Bcl-6 
and IL-21, but not CCR7 (1b).   
To determine whether there is any relationship between the frequencies of TFH and GC B cells, 
tonsillar B cell subsets were analysed by staining for CD19, CD38 and IgD. Gated for CD19+ B 
cells, GC B cells were identified as CD19+CD38+IgD- (red circle, 1c). There was a good 
correlation between the frequencies of GC B cells  (% of B cells) and TFH in NALT of children 
and adults (1d, r = 0.86, P< 0.001).   
When the frequencies of TFH (% of CD4+ T cells) in tonsillar MNC were analyzed in association 
with age, it was found that the mean frequency in children was significantly higher than in adults 
(Figure 2a), and there appeared to be an age-associated decrease in the TFH frequency (2b). The 
mean TFH frequency was shown to be highest in younger children from 1.5 to ∼10 years olds (2b),  
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3.2. TFH mediate LAIV- and inactivated antigen-induced antibody production.  
We sought to determine whether TFH play a role in the antibody response induced by current 
influenza vaccines in an immune induction site eg. NALT. Stimulation by LAIV induced a 
marked increase in TFH number in tonsillar MNC, which was correlated with a marked production 
of anti-sH1N1 HA antibodies including IgG, IgM and IgA (Figure 3a). Stimulation by the 
inactivated sH1N1 antigen induced a modest increase in TFH number which correlated with a 
modest production of IgG and with little production of IgM and IgA anti-HA antibodies (3b). 
Further, stimulation by LAIV of co-culture of purified B cells with TFH, but not with non-TFH 
cells, induced production of IgG, IgM and IgA anti-HA antibodies (3c). Again, stimulation by the 
inactivated sH1N1 antigen induced a modest IgG anti-HA in the B cell-TFH co-culture (3d), but 
no IgM and IgA response (data not shown). No antibody response was seen in the co-culture of B 
cells and non-TFH cells (3c+d).  
3.3. CpG-DNA promotes TFH and enhances anti-HA antibody production.  
To determine whether CpG-DNA could promote TFH thereby enhancing the B cell anti-HA 
antibody response, tonsillar MNC were stimulated with CpG-DNA with/without the inactivated 
sH1N1 virus antigen.  As shown in figure 4a, CpG-DNA elicited a dose-dependent increase in 
TFH frequency in tonsillar MNC. CpG-DNA at a low dose at 0.1 µg/ml, together with the sH1N1 
antigen, elicited a marked increase in TFH number (4b) which correlated with a TFH cell 
proliferative response (4c) in tonsillar MNC, and significantly higher than that elicited by the 
sH1N1 antigen alone (4b+c, p<0.01). In the meantime, CpG-DNA together with sH1N1 antigen 
elicited a marked increase in IgG, IgM, and IgA anti-HA antibody production, much higher than 
that elicited by sH1N1 antigen alone (4d).  
3.4. CpG-DNA-mediated enhancement of anti-HA antibody production involves TFH and IL21.  
To further determine whether TFH contribute to CpG-DNA mediated enhancement of antibody 
production, purified B cells were co-cultured with TFH or non-TFH cells in the presence of CpG-
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 | P a g e  
 
DNA and sH1N1 antigen. As shown in Figure 5a, production of anti-HA IgG, IgA and IgM 
antibodies were seen in the B cell co-culture with TFH, but not with non-TFH cells.  
IL21 concentrations in tonsillar MNC and the TFH-B cell co-culture were analyzed. As shown in 
Figure 5b, CpG-DNA stimulation induced an increase in IL21 concentration in the cultured 
MNC. In the TFH-B cell co-culture, following stimulation, significant production of IL-21 was 
only seen in the presence, but not in the absence of TFH (5c). Further, IL21 receptor blocking by 
the use of IL21R-Fc chimera abrogated the increase in TFH elicited by CpG-DNA and sH1N1 
antigen stimulation (5d). In the meantime, the IL-21 receptor blocking reduced the production of 
anti-HA IgA and IgM antibodies in tonsillar MNC (5e).  
3.5. Induction of TFH differentiation by CpG-DNA with influenza antigen.   
To determine whether CpG-DNA promotes induction of TFH from naïve T cells, tonsillar MNC 
depleted of CD45RO+ cells (removed effector and memory T cells including TFH) were stimulated 
with CpG-DNA with the inactivated sH1N1 antigen for 7 days. As shown in Figure 6a, the 
stimulation induced a marked increase in the number of TFH (CD4+CXCR5high) which was 
significantly higher than the sH1N1 antigen stimulation alone (p<0.01).  
3.6. Effect of pDC on TFH-mediated antibody response.   
When we analyzed TLR9 expression using flow cytometry, no significant expression was shown 
by purified TFH or non-TFH CD4+T cells (data not shown). By contrast, a proportion of B cells 
and most pDC were shown to express TLR9 (6b). Since there was a prominent number of pDC in 
tonsillar tissue which expressed a high level of TLR9, we examined the effect of pDC on CpG-
DNA and TFH mediated antibody response. Purified pDC were added to the TFH-B cell co-culture, 
and co-incubated with CpG-DNA with the inactivated sH1N1 antigen.  As shown in Figure 6c, 
the addition of pDC further enhanced the anti-HA IgM and IgA antibody production in the TFH-B 
cell co-culture.  
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4. DISCUSSION 
NALT is a unique inductive site for B-cell response and plasma cell generation in the upper 
respiratory tract, which makes the intranasal route of vaccination an attractive strategy against 
airway infection such as influenza(Brandtzaeg, 2011). As TFH are critical for T cell-dependent 
antibody response, promoting TFH in NALT may be an effective strategy for intranasal 
vaccination.  
In this study, we first studied the frequency of TFH in NALT tissue of children and adults, and 
showed that NALT of children aged 1.5-10 years contained abundant TFH (Figure 1+2). The 
finding that children as young as 1.5 years already developed a prominent number of TFH in 
NALT
 
suggests the priming of
 
TFH in early childhood is fairly efficient. It may also reflect the 
period of high level of microbial exposure in the nasopharynx which primes antigen-specific TFH 
cells during young childhood. The finding that the TFH frequency in children was higher than in 
adults
 
is consistent with the previous report by Bentebibel et al that also showed differences 
between children and adults in the TFH subsets including CXCR5highICOShigh, CXCR5intICOSlow and 
CXCR5intICOShigh subsets (Bentebibel et al., 2013). 
We then studied the function of TFH in human NALT, and more specifically on whether the TFH 
play an important role in influenza antigen-induced antibody response. We showed that 
stimulation by LAIV elicited a marked increase in TFH number in tonsillar MNC that correlated 
with a strong production of anti-sH1N1 HA IgG, IgM and IgA antibodies (Figure 3a). By 
comparison, stimulation by an inactivated sH1N1 antigen elicited a small increase in TFH that 
correlated with a modest anti-HA antibody production which was predominantly IgG (Figure 3b). 
Further, we demonstrated that the antibody responses induced by both LAIV and the inactivated 
sH1N1 antigen were dependent on the presence of TFH in the co-culture with B cells (Figure 
3c+d). These results support the hypothesis that TFH may be critical in influenza vaccine-induced 
anti-HA response in humans(Bentebibel et al., 2013; Spensieri et al., 2013).  
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Information on antibody responses to influenza antigens in human NALT is limited. Our results 
on antibody responses in the NALT tissue induced by LAIV and the inactivated sH1N1 antigen 
are in general consistent with previous findings that intranasally administered LAIV induced 
prominent antibody responses including IgA and IgG in nasal lavage mucosal samples 
(Moldoveanu et al., 1995), and the inactivated antigen elicits primarily an IgG-predominant 
memory response (Bentebibel et al., 2013). Given that many subjects would have been exposed 
previously to infection of various strains of influenza viruses, it is plausible that these previous 
contact induced memory and would to some degree have impact on the antibody response tested 
in this study. The relative predominance of IgG antibody production is concordant with the 
general predominance of IgG immunocytes in adenotonsillar tissue (Boyaka et al., 2000). A live-
attenuated vaccine, which resembles more closely to a natural infection, is generally used without 
an adjuvant and activates a stronger innate and broader immune response than an inactivated 
vaccine(Siegrist, 2013; Sridhar et al., 2015). For an inactivated virus antigen, an adjuvant is 
usually needed and some adjuvants have been shown to greatly augment the immune response 
induced by inactivated influenza vaccines(Nicholson et al., 2001). 
We further studied whether an adjuvant could be used to promote TFH and by which enhances the 
antibody response induced by the inactivated influenza antigen. CpG-DNA, as a TLR9 ligand, 
has been studied as a candidate adjuvant.  We found that CpG-DNA stimulation of tonsillar MNC 
promoted the TFH number in a dose-dependent manner. Also, a low dose of CpG-DNA (0.1ug/ml)  
with the inactivated sH1N1 antigen markedly increased TFH number, and correlated with an 
enhanced anti-HA response including IgG, IgM and IgA antibodies in tonsillar MNC (Figure 4), 
a pattern similar to that induced by LAIV. Furthermore, the enhanced anti-HA antibody response 
was observed only in the co-culture of B cells with TFH but not with non-TFH cells following 
stimulation by the antigen and CpG-DNA (Figure 5a). These suggest that with the inactivated 
influenza virus, CpG-DNA may promote influenza-specific TFH, and thereby enhances the TFH 
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mediated antibody response, including both primary and memory anti-influenza responses. These 
results are concordant with the recent reports in mouse models that CpG-DNA could increase TFH 
and B cell responses (Chakarov and Fazilleau, 2014; Mastelic et al., 2012; Rookhuizen and 
DeFranco, 2014).  
IL-21 has been suggested to play an important role in TFH differentiation(Rodríguez-Bayona et 
al., 2012). We showed that stimulation with CpG-DNA enhanced IL-21 production that was 
correlated with the expansion of TFH in tonsillar MNC. Further we showed that it was mainly the 
TFH but not non-TFH CD4+T cells produced IL-21. IL-21 receptor blocking inhibited the increase 
in TFH number and anti-HA antibody production induced by CpG-DNA with sH1N1 antigen 
(Figure 5). These findings support an important role of IL-21 in CpG-DNA mediated expansion 
of TFH and in the enhanced B cell antibody production.  
Whereas no significant expression of TLR9 was shown in TFH cells, both B cell and pDC in 
NALT were shown to express TLR-9 (Figure 6).  It is possible that CpG-DNA promotes TFH 
number and function in tonsillar MNC through both B cell and pDC. We found that the addition 
of pDC to TFH-B cell co-culture enhanced the anti-HA antibody production following stimulation 
by CpG-DNA and sH1N1 antigen. This suggests that pDC contributes to TFH function in 
mediating B cell antibody response. The addition of pDC enhanced mainly IgM and IgA but not 
IgG response, which may suggest that pDC contributes mainly to TFH-mediated primary antibody 
response (mainly IgM and IgA). It has been reported that the TFH equivalent CXCR5+CD4+ T 
cells in circulation were efficient to help memory B cells for memory antibody response 
(predominantly IgG), but were unable to help naïve B cells(Bentebibel et al., 2013). By activation 
of pDC, CpG-DNA may enhance TFH-mediated primary B cell anti-HA response induced by an 
inactivated virus antigen. An optimal primary response is likely to be critical for effective 
immunization in young children or that against a new avian influenza virus infection in humans. 
CpG-DNA has a strong immunostimulatory effects on pDC (Krug et al., 2001a; Krug et al., 
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2001b; Rothenfusser et al., 2002) and pDC has been shown to be important in anti-influenza and 
anti–rotavirus antibody responses upon virus infection/stimulation (Deal et al., 2013; Jego et al., 
2003). Considering that tonsillar tissue contains a prominent number of pDC (Polak et al., 2008; 
Rescigno, 2013) (Summers et al., 2001), this contribution by pDC to TFH-mediated antibody 
response in NALT tissue may be explored in future vaccination strategy against respiratory 
infection.  
In conclusion, abundant TFH exist in NALT of young children which suggests efficient TFH 
priming and it will be possible to prime TFH effectively in NALT through immunization during 
early
 
childhood. TFH cells are critical in human mucosal anti-influenza antibody responses in 
NALT tissue. Use of an immunological adjuvant such as CpG-DNA that has the capacity to 
promote TFH and thereby to enhance influenza antigen-induced antibody response in NALT may 
have important implications for novel vaccination strategies, such as mucosal vaccines against 
respiratory infections such as influenza.  
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Figure legends 
Figure 1. Identification of TFH in tonsillar tissues of children and adults, and relationship 
with GC B cells. Adenotonsillar MNC were stained with anti-human CD3, CD4, CXCR5 and 
ICOS antibodies followed by flowcytometry (a). Within CD4+ Tcells (R2), TFH were identified 
as CXCR5high ICOShigh CD4+ T cells (red, R3). In addition to CXCR5 and ICOS,  the designated 
TFH population were also shown to express Bcl-6 and IL-21, but not CCR7 (b).  GC B cell was 
identified as CD38++ IgD- CD19+ (c, red circle), and the relationship between the frequencies of 
TFH and GC B cells  (% of B cells) in tonsillar MNC is shown (d, r = 0.86, n=16, P< 0.001).   
 
Figure 2. Frequencies of TFH in children and adults. Tonsillar TFH frequencies (expressed as 
the % of TFH in CD4+ T cells) were compared between children (n=80) and adults (n=30) (a), and 
the relationship between the TFH frequencies and age is shown (b, r=-0.62, n=110, p<0.001).  
Figure 3. TFH mediate LAIV and inactivated virus antigen-induced antibody production in 
NALT. Tonsillar MNC were stimulated by LAIV (2ul/ml, approx. 105FFU/ml) (a) and the 
inactivated seasonal virus (sH1N1) antigen (1ug/ml) (b) followed by analysis of TFH number and 
anti-HA IgG, IgA and IgM antibody responses using flow cytometry and ELISA respectively 
(**p<0.01, n=20, aged 2-20 years). Co-culture of purified B cells with TFH (CD4+ CXCR5high) or 
with non-TFH CD4+T cells (CD4+ CXCR5 -) were stimulated with LAIV (c) or the sH1N1 antigen 
(d), and anti-HA antibody responses were seen in the presence, but not in the absence of TFH 
(c+d, **p<0.01, n=10, aged 2-20 years). 
Figure 4. CpG-DNA promotes TFH and enhances anti-HA antibody production. Tonsillar 
MNC were stimulated by CpG-DNA with or without the inactivated sH1N1 antigen, followed by 
analysis of TFH frequency (a+b), proliferation index (c) and antibody production (d). CpG-DNA 
stimulation induced a dose-dependent increase in TFH frequency (a, *p<0.05,**p<0.01, n=10). 
TFH number (b) and proliferation index (c) in tonsillar MNC were shown following stimulation 
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with CpG-DNA (0.1 µg/ml) with or without sH1N1 antigen (1 µg/ml) (*p<0.05, **p<0.01, 
p=10). CpG-DNA together with sH1N1 antigen elicited a marked production of anti-sH1N1 HA 
IgG, IgM, and IgA antibodies (d, *p<0.05, **p<0.01, n=10, aged 2-20 years).  
 
Figure 5. CpG-DNA-mediated enhancement of anti-HA antibody production involves TFH 
and IL-21. Co-culture of purified B cells with TFH (CD4+ CXCR5high) or non-TFH (CD4+ CXCR5-
) cells were stimulated with CpG-DNA (0.1µg/ml) and sH1N1 antigen (1µg/ml), followed by 
analysis of anti-HA IgG, IgA and IgM antibody production (a, **p<0.01, n=20, aged 2-20 years). 
IL-21 concentrations in tonsillar MNC (b, **p<0.01, n=20) and in the co-culture of B cells with 
TFH or non-TFH (c, **p<0.01, n=15) were analyzed following stimulation by CpG-DNA 
(0.1µg/ml). IL-21R-Fc chimera or isotype control was co-incubated with tonsillar MNC in the 
presence of CpG-DNA and sH1N1 antigen, followed by analysis of TFH frequency (d, *<0.05) 
and IgA and IgM antibody production (e, **p<0.01), n=15, aged 2-20 years). IgG was not shown 
because of the cross-reactivity to the Fc portion of IL-21R-Fc. 
Figure 6. Induction of TFH from naive CD4+ T cells by CpG-DNA and antigen, and effect of 
pDC on TFH-mediated antibody response. Tonsillar MNC depleted of CD45RO+ T cells were 
stimulated with CpG-DNA (0.1µg/ml) and sH1N1 antigen for 7 days. CD45RO+ cell depletion 
removed effector and memory T cells including TFH from tonsillar MNC but retained naïve T 
cells. CpG-DNA with sH1N1 antigen induced a significant number of TFH differentiation from 
naïve T cells in tonsillar MNC (a, *p<0.05, **p<0.01, ***p<0.001, n=16, aged 2-20 years). A 
representative figure shows expression of TLR9 in tonsillar B cells and pDC (b). Purified pDC 
was added to the co-culture of purified TFH and B cells followed by stimulation by CpG-DNA 
and sH1N1 antigen.  The addition of pDC was shown to enhance HA-specific IgA and IgM, but 
not IgG antibody production induced by CpG-DNA and sH1N1 antigen (c, *p<0.05, n=10, aged 
2-20 years).  
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• We analysed the role of TFH cells in anti-influenza response in human immune tissue.  
• TFH are critical for anti-influenza antibody response following vaccine stimulation. 
• CpG-DNA can promote TFH and by which enhances antigen-specific antibody response.  
 
